ClinicalTrials.gov ID NCT05605522Sponsor Fusion Pharmaceuticals Inc.Local PI Rebecca WongConditions This is a first-in-human, Phase 1, non-randomized, multi-centre, open-label clinical trial designed to investigate the safety, tolerability, dosimetry, biodistribution, and pharmacokinetics (PK) of -FPI-2059 and -FPI-2058, as well as the pharmacodynamics…
Study of RYZ101 Compared with SOC in Pts W Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy (ACTION-1)
ClinicalTrials.gov ID NCT05477576Sponsor RayzeBio, Inc.Local PI Rebecca WongConditions This study aims to determine the safety, pharmacokinetics (PK) and recommended Phase 3 dose (RP3D) of RYZ101 in Part 1, and the safety, efficacy, and PK of RYZ101 compared with investigator-selected standard…
(Ac-225)-PSMA-62 Trial in Oligometastatic Hormone Sensitive and Metastatic Castration Resistant Prostate Cancer (ACCEL)
linicalTrials.gov ID NCT06229366Sponsor POINT Biopharma, a wholly owned subsidiary of Eli Lilly and CompanyLocal PI Di Maria JiangConditions The primary aim of the phase Ia study is to evaluate the safety and tolerability of -PSMA-62 to determine the maximum tolerated dose…
A Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients With PSMA PET Scan Positive CRPC (PSMACare)
ClinicalTrials.gov ID NCT05849298Sponsor Novartis PharmaceuticalsLocal PI Robert HamiltonConditions The purpose of this study is to evaluate the efficacy and safety of AAA617 alone (Lutetium vipivotide tetraxetan) and in combination with an Androgen Receptor Pathway Inhibitors (ARPI) in participants with…
An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC. (PSMA-DC)
ClinicalTrials.gov ID NCT05939414Sponsor Novartis PharmaceuticalsLocal PI Andrew McPartlinConditions All participants will be assessed for eligibility and will undergo baseline disease assessments including a mandatory gallium (68Ga) gozetotide (also known as Ga-PSMA-11) or piflufolastat (18F) ( also known asDCFPyL) PET/CT scan…
Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Patients With Early-Stage Oral Cavity Cancer
ClinicalTrials.gov ID NCT04333537Sponsor NRG OncologyLocal PI John de Almeida Conditions: PRIMARY OBJECTIVES: I. To determine if patient-reported neck and shoulder function and related quality of life (QOL) at 6 months after surgery using the Neck Dissection Impairment Index (NDII) is…
Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Patients With Early-Stage Oral Cavity Cancer
ClinicalTrials.gov ID NCT04333537Sponsor NRG OncologyLocal PI John de Almeida Conditions: PRIMARY OBJECTIVES: I. To determine if patient-reported neck and shoulder function and related quality of life (QOL) at 6 months after surgery using the Neck Dissection Impairment Index (NDII) is…
SPECT-CT Guided ELEctive Contralateral Neck Treatment for Patients With Lateralized Oropharyngeal Cancer (SELECT)
ClinicalTrials.gov ID NCT05451004Sponsor Canadian Cancer Trials GroupLocal PI John de Almeida Conditions: This study is being done to answer the following question: Is the chance of cancer spreading or returning the same if radiotherapy to the neck is guided, by…